Skip to main content
Caplight Logo









TECregen

TECregen

Private
BaselHealthcare & Life Scienceshttps://tecregen.com/

Last Round

Seed

Jan 8, 2026

Total Funding Raised

$12.6M

Momentum

Top 50%

of companies Caplight tracks

Company Overview

TECregen is a biotechnology company developing a new class of biologics, called thymopoietics, designed to regenerate the thymus and restore immune function.

Sector

Healthcare & Life Sciences

Verticals

Biotechnology, Drug Discovery, Precision Medicine

Business Model

B2B

Customer Profile

Services & Consulting

AI Layer

Non-AI

Keywords

regenerative medicinethymus regenerationbiologicsimmunotherapyprotein engineeringthymopoietic biologicsimmune restorationT-cell deficiencylongevity biotechthymic epithelial cellsdrug discoveryprecision medicinerejuvenation biotechbiotech startup

Historical Pricing

Historical view of private secondary pricing and transaction trends.

Unlock Pricing Charts

Sign up to view complete historical pricing and secondary transactions.

Caplight Momentum Score

Proprietary index based on bid/ask volume and sentiment.

View Momentum History

Track how buyer interest and sentiment changes over time.

TECregen Comparables

Compare TECregen with similar companies based on industry and business-model similarity.

TECregen comparables — related companies by embedding similarity
CompanySimilarityMarket Cap
Tolerance Bio, Inc.
80%
ThymoFox
79%
Thymmune Therapeutics
76%

TECregen Funding Rounds

Historical fundraising activity

Data table
RoundDateAmount RaisedValuationInvestorsSources
SeedJan 8, 2026

Key People

Founding team and executive leadership

Klaas Zuideveld

Chief Executive Officer

Executive Team

Market signals

Structured signals derived from secondary market and firmographic data.

  • Feb 20, 2026

    Grew 30% QoQ, from 10 to 13 employees.

  • Jan 30, 2026

    Dr. Klaas Zuideveld appointed as new Chief Executive Officer.

TECregen Filings

Explore SEC and related filing metadata, where available.

TECregen filings preview — column headings only; records require access
TypeDateAmount OfferedAmount SoldFilingPagesDownload

Filing documents are not displayed on this public page. Request access to learn about available coverage.

Request access

Frequently Asked Questions

Common questions about TECregen's valuation, stock price, and market status.

Is TECregen a public or private company?

TECregen is a private company.

What is the current stock price of TECregen?

TECregen is a private company with no public stock price. No recent secondary market data is available.

How much is TECregen worth (valuation)?

Valuation information for TECregen is not publicly available.

Can I buy TECregen stock?

TECregen shares may be available on secondary markets subject to transfer restrictions. Caplight facilitates secondary market transactions for accredited investors. Visit https://www.caplight.com to learn more.

When was TECregen's last funding round?

TECregen's most recent funding round was Seed on January 8, 2026.

Who are the main investors in TECregen?

Key investors in TECregen include Boehringer Ingelheim Venture Fund.

Will TECregen IPO soon?

No public IPO plans have been announced for TECregen.

How can I track TECregen secondary market activity?

Caplight tracks bids, offers, and trades for private companies. Visit https://www.caplight.com to monitor TECregen's secondary market activity and sign up for updates.

Firmographic Details

HeadquartersBasel
Employee Range12
Year Founded2023
Last FundingJan 8, 2026

Institutional Data Access

Join leading institutional investors using Caplight to access private market data, discover pricing, and execute secondary block trades.

Requires verified institutional or accredited status.

See something wrong or outdated?